Cancer Center

company image

University of Chicago Comprehensive Cancer Center

University of Chicago Comprehensive Cancer Center

Home to countless breakthroughs in cancer treatment, the University of Chicago Comprehensive Cancer Center is one of the world’s most accomplished cancer treatment centers.

Dr. Nicholas Vozelgang, currently on staff at the Comprehensive Cancer Center in Nevada, led a research program in 2002 that aimed to combine chemotherapy drugs pemetrexed and cisplatin. The clinic resulted in longer life expectancies for patients suffering from pleural mesothelioma.

These groundbreaking accomplishments secured a spot for the University of Chicago Comprehensive Cancer at the forefront of cancer treatment and research facilities. Lung cancer and other asbestos-related conditions are now a specialty of the University of Chicago Comprehensive Cancer Center.

The facility was designated by the National Cancer Institute (NCI) as a distinguished Comprehensive Cancer Center due to its emphasis placed on maintaining the highest standards in basic science, clinical research, cancer prevention, education, and patient care.

Mesothelioma Options at the University of Chicago

Finding a cure for malignant mesothelioma has been a primary goal of the Chicago Cancer Center for the past twenty years. The medical staff’s integrative approach has provided valuable insight to the whole world in regard to mesothelioma causes and treatments. Spearheading the center’s mesothelioma program, Dr. Hedy Lee Kindler is also the medical director of gastrointestinal oncology as well as an expert in the treatment of malignant mesothelioma, gastrointestinal tumors, and pancreatic tumors.

Acting as associate chief of thoracic and cardiac surgery, Dr. Wickii Thambiah Vigneswaran specializes in the surgical care of hyperhidrosis and mesothelioma. As head director of thoracic oncology research as well as chest oncology, Dr. Ravi Salgia specializes in thoracic cancer research, as well as mesothelioma research.

Due to its role as a part of the University of Chicago’s education institution, the cancer center has a direct line into the most cutting-edge techniques and medical advances. This access also includes equipment and expensive, world-class tools. These are a few of the many reasons that the cancer center is home to some of the world’s most accomplished surgeons, doctors, nurses, and other medical professionals.

More than two-hundred and thirty renown physicians and scientists have worked on research with the world-class institution and its affiliated university.

Clinical Trials and Research

Practicing “translational research” means that the discoveries that the clinical researchers obtain from their laboratory work are used immediately in trials and tests that arise in landmark new procedures, as well as new treatments. Such advancements have resulted in new procedures in the fields of radiation therapy, chemotherapy, and surgery.

The cancer center also offers intensity-modulated radiotherapy (IMRT), which is a novel technique that administers high-dosed, specifically aimed radiation that reduces damage to healthy organs. The cancer center also places a huge emphasis upon genetic cancer research, allowing the world to better understand the causes of various types of cancer.

Constantly involved in new cancer clinical trials, the hospital’s staff is always aiming to revolutionize the way cancer is treated. Spearheading a trial that aims to test pembrolizumab on patients with malignant mesothelioma, Dr. Kindler is hoping to be part of this change.

The University of Chicago Comprehensive Cancer Center is one of the only institutions in the country analyzing the efficacy of the immunotherapy drug Pembrolizumab on mesothelioma.

Article Sources

Page Contributors